抗Human VEGF R2/KDR抗体(Anti-Human VEGF R2/KDR antibody)

• 価格
• Product Details
• Applications and Data
• References
• Related Research Areas
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGF R2/KDR/Flk-1Ala20-Glu764Accession # P35968
Source	Monoclonal Mouse IgG1 Clone # 89109
Purification	Protein A or G purified from hybridoma culture supernatant
Specificity	Detects human VEGF R2/KDR/Flk-1 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant human (rh) VEGF R1, rhVEGF R3, or rmVEGF R2.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human VEGF R2/KDR/Flk-1 Fc Chimera (Catalog # 357-KD) under non-reducing conditions only. It is recommended to use Goat Anti-Human VEGF R2/KDR/Flk‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357).
Human VEGF R2/KDR Sandwich Immunoassay	Reagent
ELISA Capture (Matched Antibody Pair)	2-8 µg/mL	Human VEGF R2/KDR/Flk‑1 Antibody (Catalog #MAB3573 )
ELISA Detection (Matched Antibody Pair)	0.1-0.4 µg/mL	Human VEGF R2/KDR/Flk‑1 Biotinylated Antibody (Catalog #BAF357 )
ELISA Standard		Recombinant Human VEGF R2/KDR Fc Chimera Protein (Catalog #357-KD )
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.		Preparation and Storage
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.	Reconstitution Buffer Available
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF R2/KDR/Flk-1	VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGF R2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGF R2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGF R2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGF R2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

目次に戻る

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name:	Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs:	3791 (Human); 16542 (Mouse)
Alternate Names:	CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

目次に戻る

Related Research Areas

Airway Inflammation and Remodeling

Cancer Biomarkers

Cytokine and Growth Factor Receptors on VSMC

Endothelial Cell Differentiation Markers

Endothelial Cell Markers

Endothelial Progenitor and Endothelial Cell Markers

Endothelial Progenitor Cell Markers

Hemangioblasts

Hematopoietic Stem Cell Markers

HIF Transcription Factors

Myeloid-derived Suppressor Cells (MDSC)

Receptor Tyrosine Kinases (RTKs)

Receptor Tyrosine Kinases (RTKs) in the Akt Pathway

Receptors in the Jak/STAT Pathway

Semaphorins, Plexin Receptors, and Related Molecules

VEGF Family

VEGF Receptors and Regulators on Endothelial Cells

Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Authors: Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ Int. J. Cancer, 2009;124(11):2709-18. Species: Human Sample Type: Cell Culture Supernates Application: WB

目次に戻る

Related Product & Information

Background

VEGF R2/KDR/Flk-1

background_content

Background: VEGF R2/KDR/Flk-1 VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGF R2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGF R2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGF R2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGF R2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

目次に戻る

Citations

1. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
   Authors: Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ
   Int. J. Cancer, 2009;124(11):2709-18.
   Species: Human
   Sample Type: Cell Culture Supernates
   Application: WB


2. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
   Authors: Meissner M, Reichenbach G, Stein M, Hrgovic I, Kaufmann R, Gille J
   Cancer Res., 2009;69(5):1976-84.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


3. Interaction with human stromal cells enhances CXCR4 expression and engraftment of cord blood Lin(-)CD34(-) cells.
   Authors: Kobune M, Kawano Y, Takahashi S, Takada K, Murase K, Iyama S, Sato T, Takimoto R, Niitsu Y, Kato J
   Exp. Hematol., 2008;36(9):1121-31.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


4. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
   Authors: Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R
   Cancer Cell, 2004;6(5):507-16.
   Species: Human
   Sample Type: Recombinant Protein
   Application: ELISA Development

目次に戻る